Obesity-Specific Improvement of Lung Cancer Outcomes and Immunotherapy Efficacy with Metformin

Investigators hypothesized that metformin could benefit obese and overweight patients with NSCLC. They retrospectively analyzed two clinical cohorts and employed complementary mouse models to test their hypothesis. One cohort included NSCLC patients with overweight BMI and non-overweight BMI who underwent lobectomy.